Quest Diagnostics Inc. (DGX)
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics typically performs between 30 and 40 cyclospora tests a day. Now it's processing more than 1,500.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.
